You can buy or sell Tocagen and other stocks, options, ETFs, and crypto commission-free!
Tocagen Inc. Common Stock, also called Tocagen, is a clinical-stage, cancer-selective gene therapy compan. Read More It focuses on the development of product candidates designed to activate a patient's immune system against their own cancer from within. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Yahoo FinanceMar 11
Implied Volatility Surging for Tocagen (TOCA) Stock Options
Investors in Tocagen Inc. TOCA need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 21, 2019 $15 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also ...
Stock Price, News, & Analysis for Tocagen
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is als...
Seeking AlphaFeb 28
Tocagen: A Valuation
Tocagen Inc. (TOCA) is a clinical-stage company engaged in developing selective gene therapy for various cancers. The company's platform uses retroviral replicating vectors technology and its lead drug candidate is a combo of Toca 511 and Toca FC in Phase III clinical trial targeting recurrent high-grade glioma. We recently covered Tocagen in a report. This valuation article is a follow up. The Valuation sheet is available here. The valuation sheet for the company stock is divided into three sheets where A...
Expected May 9, After Hours